AzTrials
AzTrials

Kidney FailureNCT05272800

BIS-guided Fluid Management in HD Patients

A study testing Spectroscopy Bioimpedance Analysis and Clinical Examination alone in people with Kidney Failure and Haemodialysis Fluid Adverse Reaction, run by Catholic University of Pelotas at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Hemodialysis (HD) is life-sustaining in kidney failure. However, adequate fluid status depends on precise estimation of dry weight (DW), which is a goal difficult to achieve. This randomized open label controlled parallel-group trial aims to compare spectroscopy bioimpedance (BIS) guided DW estimation with clinical… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Spectroscopy Bioimpedance Analysis and Clinical Examination alone
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
110 participants
Where
1 siteBrazil
Study dates
1 Sep 2019to 1 Sep 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • CKD diagnosis,
  • 18 years or older,
  • treated by in-center HD for longer than three months,
  • HD treatment in the Dialysis and Transplantation unit of a Brazilian University Hospital.

Who cannot join

  • less than thrice a week HD session,
  • lower limbs amputation,
  • pregnancy,
  • pacemaker, implantable cardioverter-defibrillator or orthopedic protheses use.

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Hospital Universitário São Francisco de Paula

    Pelotas, Rio Grande do Sul, 96020-260

Other trials in Brazil

About this study

Official title: Effects of Bioimpedance-guided Fluid Management in Maintenance Hemodialysis Patients -

Hemodialysis (HD) is life-sustaining in kidney failure. However, adequate fluid status depends on precise estimation of dry weight (DW), which is a goal difficult to achieve. This randomized open label controlled parallel-group trial aims to compare spectroscopy bioimpedance (BIS) guided DW estimation with clinical evaluation alone. Maintenance HD patients above 18 years old were randomized to monthly clinical evaluation (CE) alone or added to twice a year BIS-guided DW estimation. Randomization was performed through random number table. Follow-up lasted up to two years. Primary outcome was survival time and secondary outcomes were rate of hospital admissions, systolic and diastolic blood pressure (BP) change and number of prescribed antihypertensive drugs.

Read the detailed description

The study was designed as a randomized controlled open label and parallel trial, including adult chronic kidney disease (CKD) patients (older than 18 years) on in-center HD for longer than three months in the Dialysis and Transplantation unit of a southern Brazilian University Hospital. The exclusion criteria were less than thrice a week HD session, lower limbs amputation, pregnancy and pacemaker, implantable cardioverter-defibrillator or orthopedic protheses use. All eligible patients or their relatives were asked to sign an informed consent form before inclusion in the trial. The enrollment was performed from September 2019 to September 2021.

The research protocol was approved by the Catholic University of Pelotas Ethics Committee.

The randomization was performed by blocs according to dialysis shifts, using random number table created in Stata 15.1 statistical software (StataCorp, College Station, TX) Participants and researchers were not blinded due to the nature of the intervention. The statistical analysis was performed by a blinded evaluator.

The main outcome was all-cause two-year survival. Secondary outcomes include overall hospitalization rate and according causes, systolic and diastolic BP change (mean of the three last post-dialysis BP measurement - mean of the three first post-dialysis BP measurement), number of anti-hypertensive drug classes used after intervention time.

At inception, eligible patients had their sex, age and dry weigh recorded from electronic clinical records before the randomization to one of two groups: 1) BIS, whose dry weight is evaluated monthly by clinical examination and biannually BIS-guided; 2) CE, whose dry weight is evaluated monthly by clinical examination alone. The follow-up time for primary and secondary outcomes was two years. Data for hospitalizations, deaths, cause of death, and anti-hypertensives in use were collected from the electronical medical registry.

Procedures and Equipment Bioimpedance spectroscopy Patients randomized to BIS group were submitted to an initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany). The BCM provides information on extracellular (ECW), intracellular (ICW) and total body water through a range of electric frequencies from 5 to 1,000 kilohertz (kHz). Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care). BIS has been validated as an accurate estimator of extracellular volume against dilution techniques in HD patients.

  1. Clinical Examination The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for edema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos@, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann@, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff. Lung examination was performed using the same stethoscope placed on posterior and anterior chest during an entire inspiration and expiration periods. Lower limbs were examined by pressing the indicator toe over the ankle and pretibial area searching for pitting edema.

Data Analysis The minimal required sample size was calculated based on the expected difference in the main outcome (survival in two years) between intervention (BIS) and control (CE) groups. According to previous publications on chronic HD mortality, we intended to find a difference in survival of 20% between groups, resulting in a minimal sample of 134 patients (67 in each group), to obtain an alpha error below 5% and an 80% power.

The distribution of the variables was tested by Shapiro-Wilk. Parametric variables were described as mean and standard deviation and non-parametric by median and interquartile range. The survival analysis was performed using Cox Proportional Hazard Regression. The hospitalization density-rate, point estimates and confidence interval for the incidence-rate ratio was calculated. The number of anti-hypertensive classes (0, 1, ≥2) were compared between groups by Person's chi-square. The difference between baseline and final systolic and diastolic blood pressure was tested by student's t test. The statistical package Stata 15.1 (StataCorp, College Station, TX) was used in analysis.

Being tested
Spectroscopy Bioimpedance Analysis, Clinical Examination alone
Medical subject headings
Renal Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Spectroscopy Bioimpedance AnalysisDevice

    Also called BIS

    Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).

  • Clinical Examination aloneOther

    Also called CE

    The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.

Study groups in NCT05272800
Study groupRoleWhat they receive
BIS GroupExperimentalDry weight is evaluated monthly by clinical examination and biannually BIS-guided.
Receives: Device: Spectroscopy Bioimpedance Analysis
CE GroupActive comparatorDry weight is evaluated monthly by clinical examination alone.
Receives: Other: Clinical Examination alone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Survival

    Survival curve

    Measured: two years

Secondary outcomes (3)
  1. Hospital Admissions

    Hospital admissions rate

    Measured: two years

  2. Systolic and Diastolic Blood pressure

    Systolic and diastolic blood pressure change from baseline

    Measured: two years

  3. Anti-hypertensive medication

    Number of classes of anti-hypertensive medications in use

    Measured: two years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Mar 2022
  2. Study start1 Sep 2019
  3. Primary completion1 Sep 2021
  4. Study completion1 Sep 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
A randomized open label controlled parallel-group trial aims to compare spectroscopy bioimpedance (BIS) guided DW estimation with clinical evaluation alone.
Masking
None (open label)
Enrolment
110 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05272800
Sponsor's protocol ID
3.484.130
Status last verified
Mar 2022
First submitted
28 Feb 2022
Last updated
24 Mar 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: After publication, include data in a data repository (Harvard Dataverse)

Publications

  • Stigger K, Ribeiro LR, Cordeiro FM, Bohlke M. Incidence of hospital admissions in bioimpedance-guided fluid management among maintenance hemodialysis patients-Results of a randomized controlled trial. Hemodial Int. 2023 Jul;27(3):318-325. doi: 10.1111/hdi.13076. Epub 2023 Apr 17.

    PubMed 37067785

Questions about this trial

What is this clinical trial studying?

A study testing Spectroscopy Bioimpedance Analysis and Clinical Examination alone in people with Kidney Failure and Haemodialysis Fluid Adverse Reaction, run by Catholic University of Pelotas at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Survival (time frame: two years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05272800, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2022; AzTrials last refreshed its copy on 1 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in